Comparative analysis of clinical effectiveness of α1-adrenoblockers doxazosin, tamsulosin and silodosin in males with chronic non-inflammatory prostatitis

Abstract

Aim. Comparative study of clinical effectiveness of doxazosin, tamsulosin and silodosin as monotherapy for patients with chronic non-inflammatory prostatitis.

Methods. Outpatient medical records (OMR) of patients with the diagnosis of chronic non-inflammatory prostatitis who were treated in “The clinic of ambulatory urology” (Kazan) in 2012-2017, were analyzed: all 173 OMR of patients receiving doxazosin 1 mg QD for 30 days as monotherapy; all 150 OMR of patients receiving doxazosin 2 mg per day BID for 30 days as monotherapy; all 54 OMR of patients receiving doxazosin 4 mg per day BID for 30 days as monotherapy; all 77 OMR of patients receiving tamsulosin 0.4 mg QD for 30 days as monotherapy; all 36 OMR of patients receiving silodosin 8 mg QD for 30 days as monotherapy. Based on these OMR the “Clinical index of chronic prostatitis” (CI CP) was analyzed before the start of pharmacotherapy and 30 days after the beginning. According to the clinical index, the discrete sample was ordered containing the values of CI from 0 points (no complaints) to 50 points (maximal score - the most marked symptoms).

Results. Before the beginning of the treatment every sample of patients is homogeneous and after 30-day treatment they lose homogeneity and tend to divide into several homogeneous samples.

Conclusion. Clinical effectiveness of doxazosin, tamsulosin and silodosin in men with CNP varies in wide range, is poorly predictable, poorly explainable and needs further studies according to the principles of modern evidence-based medicine.

Keywords

chronic prostatitis / doxazosin / tamsulosin / silodosin

References

[1] Khafiz’yanova R.Kh., Burykin I.M., Aleeva G.N. Matematicheskaya statistika v eksperimental'noy i klini­cheskoy farmakologii. (Mathematical statistics in experimental and clinical pharmacology.) Kazan: Meditsina. 2006; 374 p. (In Russ.)

[2] Хафизьянова Р.Х., Бурыкин И.М., Алеева Г.Н. Математическая статистика в экспериментальной и клинической фармакологии. Казань: Медицина. 2006; 374 с.

[3] Glantz S.A. Mediko-biologicheskaya statistika. (Medico-biological statistics.) Moscow: Praktika. 1998; 459 p. (In Russ.)

[4] Гланц С. Медико-биологическая статистика. Пер. с англ. М.: Практика. 1998; 459 c.

[5] Sizova T.M. Statistika. (Statistics.) Saint-­Petersburg: ITMO. 2005; 190 p. (In Russ.)

[6] Сизова Т.М. Статистика. СПб.: ИТМО. 2005; 190 c.

[7] Loran O.B., Segal A.S. A system of comprehensive assessment of symptoms in chronic prostatitis. Urologiya. 2001; 5: 16–19. (In Russ.)

[8] Лоран О.Б., Сегал А.С. Система суммарной оценки симптомов при хроническом простатите. Урология. 2001; 5: 16-19.

[9] Uro­logiya: natsional'noe rukovodstvo. (Urology: the ­national guide.) Ed. by N.A. Lopatkin. Moscow: ­GEOTAR-Media. 2009; 1024 p. (In Russ.)

[10] Урология: национальное руководство. Под ред. Н.А. Лопаткина. М.: ГЭОТАР-Медиа. 2009; 1024 с.

[11] Urologiya. Klinicheskie rekomendatsii. (Uro­logy: clinical guidelines.) Ed. by N.A. Lopatkin. 2nd ed. Moscow: GEOTAR-Media. 2013; 416 p. (In Russ.)

[12] Урология. Клинические рекомендации. Под ред. Н.А Лопаткина. 2-е изд., перераб. М.: ГЭОТАР-Медиа. 2013; 416 с.

[13] Integrativnaya urologiya. Ruko­vodstvo dlya vrachey. (Integrative urology. Guide for physicians.) Ed. by Glybochko P.V., Alyaev Yu.G. Moscow: Medforum. 2014; 432 p. (In Russ.)

[14] Интегративная урология. Руководство для врачей. Под ред. П.В. Глыбочко, Ю.Г. Аляева. М.: Медфорум. 2014; 432 с.

[15] Zhirnikova M.L., Vinarov A.Z., Mashkovskiy M.D., Pytel’ Yu.A. The blockers of alpha-­adrenoreceptors in therapy of patients with voiding disorders. The plenum of The Russian Society of urologists. Saratov, 1994; 88–96. (In Russ.)

[16] Жирникова М.Л., Винаров А.З., Машковский М.Д., Пытель Ю.А. Блокаторы альфа-адренорецепторов в терапии больных с расстройствами мочеиспускания. Пленум Всероссийского общества урологов. Саратов, 1994; 88-96.

[17] Lobka­rev A.O., Kha­fiz’yanova R.Kh., Lobkarev O.A. Comparative study of the influence of tadalafil and doxazosin on the rate of oxygen consumption by the prostate tissue. Medicus. 2017; (4): ­71–74. (In Russ.)

[18] Лобкарев А.О., Хафизьянова Р.Х., Лобкарев О.А. Сравнительное изучение влияния тадалафила и доксазозина на скорость потребления кислорода тканью простаты. Medicus. 2017; (4): 71-74.

[19] Ziganshin A.U., Ziganshina L.E. P2-retseptory: perspektivnaya mishen' dlya budushchikh lekarstv. (P2-receptors: promising target for future drugs). Moscow: GEOTAR-Media. 2009; 136 p. (In Russ.)

[20] Зиганшин А.У., Зиганшина Л.Е. Р2-рецепторы: перспективная мишень для будущих лекарств. М.: ГЭОТАР-Медиа. 2009; 136 c.

[21] Ziganshin A.U., Bedova D.V., Zubkov E.A., Sitdykova M.E. P2-receptors of the urinary bladder as potential targets for novel drugs. Kazanskiy meditsinskiy zhurnal. 2018; (3): 462–466. (In Russ.)

[22] Зиганшин А.У., Бедова Д.В., Зубков Э.А., Ситдыкова М.Э. Р2-рецепторы мочевого пузыря как потенциальные мишени действия новых лекарств. Казан. мед. ж. 2018; (3): 462-466. DOI: 10.17816/KMJ2018-462.

RIGHTS & PERMISSIONS

Lobkarev A.O., Khafiz'yanova R.K., Lobkarev O.A.